HYW yields 542.15% · JNJ yields 2.13%● Live data
📍 HYW pulled ahead of the other in Year 1
Combined, HYW + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HYW + JNJ for your $10,000?
Hywin Holdings Ltd., through its subsidiaries, provides wealth management, insurance brokerage, and asset management service in China. It distributes private market investment products comprising asset-backed products, such as real estate securitization products, and equity investments in real estate projects or private project companies; venture capital, private equity, and hedge funds; and supply chain financing products, cash management products, and funds managed by its subsidiaries. The company also offers public market investment products, including money market funds, such as government bonds, central bank bills, term deposits, certificates of deposits, and corporate commercial papers; government bonds, corporate bonds, convertible bonds, and other traded debt instruments; and equities and multi-strategy funds. In addition, it provides individual whole life insurance, individual term life insurance, universal life insurance, individual health insurance, and annuity insurance products, as well as critical illness insurance comprising personal accident insurance products; discretionary and advisory mandates to ultra-high-net-worth clients; and overseas property investment services for residential properties, as well as client referrals to overseas property developers. Further, the company manages and distributes a range of private funds to professional investors; and offers information technology services, including transaction process management, data analysis, and system maintenance services to asset management service and financial product providers. The company was founded in 2006 and is headquartered in Shanghai, China. Hywin Holdings Ltd. is a subsidiary of Grand Lead Group Limited.
Full HYW Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.